medRxiv PreprintsInternational11 November 2026
Assessing the Accuracy of the NeuroBooster Array for GBA1 Variant Detection
This is an official announcement record
Firsthand records what medRxiv Preprints announced and links to the original. The wording below is theirs, not ours.
GBA1 variants are major Parkinson's disease risk factors, but their detection is challenging. We compared NeuroBooster Array (NBA) genotyping with reference sequencing in 3,744 individuals. NBA correctly identified 520/608 carriers (85.5%). Of 89 missed calls, 73 had no matching probe and 16 had missing calls. 25 participants had false positive calls. NBA should not be used alone for clinical decisions, but is very useful for case control analysis.
Read the official announcement
Opens www.medrxiv.org
More from medRxiv Preprints
- Silent Drift and Site-level Variance in Clinical AI: Real-world performance and subgroup analysis for post-market monitoring of an FDA-cleared artificial intelligence (AI) triage tool for high-risk use case of pulmonary embolism12 November 2026
- Determinants of mpox vaccine acceptance among peri-urban residents in Sekondi-Takoradi, Western Region of Ghana: A community-based cross-sectional study12 November 2026
- Mapping disordered eating symptoms in the ABCD Study through the Eating Disorder Symptom Index12 November 2026
- Influenza Vaccination and Disease Severity Among Older Adults Hospitalized with Influenza in France: A Nationwide Cohort Study, 2016-202412 November 2026
- Associations of drinking water per- and polyfluoroalkyl substances with cause-specific mortality in men with prostate cancer12 November 2026
This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program: especially if you are pregnant, nursing, taking medication, or managing a health condition.